Oncobiologics launches Phase I clinical trial for Humira biosimilar

June 13, 2014 7:25 AM

Oncobiologics, Inc. announced that it has received approval to initiate a Phase I clinical trial in Europe for its first biosimilar molecule, ONS-3010, a highly biosimilar version of the marketed drug, Humira.

After reviewing Oncobiologics’ Clinical Trial Application, the Centrale Commissie Mensgebonden Onderzoek (CCMO), the Dutch Competent Authority, has provided a Letter of No Objection, and the Independent Ethics Committee of the Foundation “Evaluation of Ethics in Biomedical Research” has approved a Phase I trial to be conducted by the Center for Human Disease Research in Leiden, The Netherlands.  The study is expected to be completed before the end of 2014.

“After a very successful development campaign, we are excited to see our first biosimilar molecule enter this Phase I study.  This represents the culmination of two years of hard work by our team, as well as proof-of-concept for our biosimilars business model, BioSymphony, which integrates our world-class CMC and manufacturing capabilities with the external clinical expertise of inVentiv Health, a top global CRO, and several regionally strong commercial partners around the world,” commented Oncobiologics Founder & CEO, Pankaj Mohan, Ph.D.

Aldeyra CEO Todd C. Brady M.D., Ph.D. added, “As an advisor, I have witnessed the rapid development of Oncobiologics and am thrilled to see the company take this exciting step. Oncobiologics has built a team of respected industry leaders within the framework of an agile startup. It is a testament to that team that Oncobiologics has been able to satisfy the challenging regulatory hurdles surrounding the development of complex mAb biosimilars.  I look forward to the successful completion of this trial as well as the continued advancement of other potential products in the Oncobiologics pipeline.”

Oncobiologics is developing several additional biosimilars, including a biosimilar version of Avastin, which will be filed for its first clinical trial later in 2014.  Oncobiologics is also pursuing biosimilar versions of Herceptin, Rituxan and Erbitux with plans to initiate studies in 2015 and thereafter.

Source: Oncobiologics press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!